Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

NCT04157140 | Unknown Phase 2 DMC

• 1 other identifier: 320.6750.19089-49
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 3

Brief Summary

A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with radiofrequency ablation (RFA) and transcatheter arterial chemoembolization(TACE) in patients with middle-advanced hepatocellular carcinoma(HCC)

Conditions

Hepatocellular Carcinoma

Keywords

anlotinib; HCC; TACE; RFA

Outcome Measures

Primary Outcomes (1)

• Time To Progression(TTP)

  Time To Progression is defined as the time from first day of TACE treatment until the first date of either objective disease progression

  each 42 days up to progressive disease (PD) (up to 24 months)

Secondary Outcomes (4)

• Objective Response Rate (ORR)

  each 42 days up to intolerance the toxicity or PD (up to 24 months)

• Disease Control Rate (DCR)

  each 42 days up to intolerance the toxicity or PD (up to 24 months)

• Duration of Response (DOR)

  Time Frame: each 42 days up to intolerance the PD or death (up to 24 months)

• Incidence of Treatment-Emergent Adverse Events

  Until 30 day safety follow-up visit

Study Arms (1)

Anlotinib+ TACE+ RFA

EXPERIMENTAL

Anlotinib+ TACE+ RFA

Drug: Anlotinib; Device: TACE+RFA

Interventions

Anlotinib DRUG

12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.

Anlotinib+ TACE+ RFA

TACE+RFA DEVICE

TACE first, followed by RFA within day7（+/-3days）

Anlotinib+ TACE+ RFA

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients participate in the study voluntarily and sign informed consent with good compliance.
• Histological or cytological confirmation of unrespectable middle-advanced hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage Category C or B , liver function child-Pugh class A or B (≤7 points).
• At least one measurable lesion, with diameter ≥ 10mm measured by spiral MRI/CT scan per mRECIST; have not received local therapies including but not limited to TACE, RFA, radiotherapy and cryosurgery.-Eastern Cooperative Oncology Group Performance Status 0 or 1.
• Life expectancy of at least 3 months.
• Main organs function is normal. (normal main organs function as defined below: Hemoglobin (Hb) ≥ 90 g/L, Neutrophils (ANC) ≥ 1.5×109/L, leucocyte (WBC) ≥ 3.0×109/L, Platelet count (PLT) ≥ 70×109/L, Total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 ×ULN, Serum creatinine (Cr) ≤ 1.5× ULN or Creatinine Clearance rate(CCr) ≥60ml/min,Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) \> 50%)
• The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 3 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 8 weeks after it.
• Patients have disease that is not amenable to potentially curative transplantation or ablation
• Patients who have characterization for targeted therapy treatment, but under poor economic conditions and cannot afford angiogenesis inhibitors recommended by current guidelines, including Lenvatinib, sorafenib, Cabozantinib, Ramolumab, regorafenib, etc.

You may not qualify if:

• History of other malignancy within 5 years or for now (except for non-melanoma skin cancer, cervix in situ carcinoma, superficial Bladder neoplasms).
• Subject has obstacle in the function of major organs such as heart, lung, liver and kidney
• Patients who plan liver transplantation.
• Patients who had previously received treatment with target inhibitors or other immunotherapy against or chemotherapy
• Patients who had previously received treatment with TACE or or other local therapy or radiotherapy or Chinese medicine treatment within 4 weeks.
• Liver function status Child-Pugh Class C, with malignant ascites.
• Participated in other anti-tumor clinical trials within 4 weeks.
• Symptoms that affect oral medication and cannot be controlled through proper treatment (such as inability to swallow, chronic diarrhoea and intestinal obstruction, etc.).
• Any of the following coagulation functions are abnormal, including: Prothrombin time (PT)\>ULN+4s, Activated partial thromboplastin time (APTT) \>1.5ULN s, nternational normalized ratio (INR)\>1.5
• Patients who underwent major surgery within 4 weeks.
• Patients who have got non remissive toxic reactions derived from any treatment, which is over level 1 in CTC AE (4.0).
• Patients with any severe and/or unable to control diseases，including： Patients with unsatisfactory blood pressure control using antihypertensive drugs (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100) mmHg); Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QTc≥480ms) and patients with Grade 2 or higher congestive heart failure (NYHA Classification); Patients with active or unable to control serious infections, which is over level 2 in CTC AE (4.0); Patients with poorly controlled diabetes (fasting blood glucose(FBG)\>10mmol/L); Patients with kidney failure who require hemodialysis or peritoneal dialysis; Patients with a history of immunodeficiency, including a positive HIV test or other acquired, congenital immunodeficiency disease, or a history of organ transplantation; Urine routine indicates that urine protein ≥ ++, and confirmed 24-hour urine protein quantitation \> 1.0 g.
• Patients whose tumors had invaded important blood vessels by imaging or who, as determined by the researchers, were likely to invade important blood vessels during follow-up trial, resulting in fatal bleeding.
• Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism.
• Regardless of the severity, patients with any physical signs or history of bleeding, patients with bleeding or bleeding events greater than or equal to CTCAE 3 within four weeks prior to the first administration, or patients with unhealed wounds, fractures, ulcers.

Sponsors & Collaborators

• Jinglong Chen: lead

Study Sites (3)

Beijing Ditan Hospital, Capital Medical University

Beijing, Beijing Municipality, 100011, China

RECRUITING

The First Affiliated Hospital of Dalian Medical University

Dalian, China

NOT YET RECRUITING

Shengjing Hospital Of China Medical University

Shenyang, China

NOT YET RECRUITING

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Interventions

anlotinib

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Central Study Contacts

XiaoYan Ding, M.D

CONTACT

13811560276; dingxiaoyan198111@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Chief of Oncology

Study Record Dates

• First Submitted: November 6, 2019
• First Posted: November 8, 2019
• Study Start: November 28, 2019
• Primary Completion: September 1, 2022
• Study Completion: March 30, 2023
• Last Updated: December 3, 2019

Record last verified: 2019-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (3)